- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02910570
Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis
The Association Between Weight Loss With Subsequent Maintenance Using Liraglutide and Changes in Skin Autoflouresence in Overweight or Obese Patients With Knee Osteoarthritis - a Substudy to "Effect of Liraglutide on Body Weight and Pain in Overweight or Obese Patients With Knee Osteoarthritis: A Randomised, Double Blind, Placebo-controlled, Parallel Group, Single-centre Trial" (NCT02905864)
This is sub-study to a randomised, double blind, placebo-controlled, parallel group, and single-centre trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864).
In the parent trial patients will be subjected to a run-in diet intervention phase (week -8 to 0) including a low-calorie diet and dietetic counselling. At week 0 patients will be randomised to receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle.
This sub-study of the parent trial only involves an additional assessment of skin auto fluorescence (AGE concentration) in the preallocation phase and in the main trial phase, i.e. from enrollment (defined as signature of informed consent) to treatment allocation (visits -Tx and T0 in the parent trial visit schedule) and from allocation to end of trial (visits T0 and T15 in the parent trial visit schedule).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Capital Region
-
Frederiksberg, Capital Region, Denmark, 2000
- Department of rheumatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Same as parent trial (NCT02905864)
Inclusion Criteria:
- Informed consent obtained
- Clinical diagnosis of knee OA (American College of Rheumatology (ACR) criteria) confirmed by radiology but restricted to definite radiographic OA at early to moderate-stages (Kellgren-Lawrence grades 1, 2, or 3)
- Age ≥ 18 years and < 75 years
- Body mass index (BMI) ≥ 27 kg/m2
- Stable body weight during the previous 3 months (< 5 kg self-reported weight change)
- Motivated for weight loss
Exclusion Criteria:
- On-going participation, or participation within the last 3 months, in an organised weight loss programme (or within the last 3 months)
- Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial
- Current use or use within three months before this trial of GLP-1 receptor agonist, pramlintide, sibutramine, orlistat, zonisamide, topiramate, or phentermine
- Type 1 diabetes
- Type 2 diabetes treated with glucose-lowering drugs other than metformin
- Alloplasty in target knee joint (see section 6.3)
- End stage disease in target knee joint (Kellgren-Lawrence grade 4)
- Immuno-inflammatory disease
- Chronic wide-spread pain
- Pregnancy or insufficient anti-conception therapy for female fertile patients
- Breast-feeding
- Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 x above upper normal range (UNR)
- Surgery scheduled for the trial duration period, except for minor surgical procedures
- Surgical procedures such as arthroscopy or injections into a knee within 3 months prior to enrolment
- Previous surgical treatment for obesity (excluding liposuction >1 year before trial entry)
- Thyroid stimulating hormone (TSH) outside of the range of 0.4-6.0 mIU/L
- Obesity secondary to endocrinologic or eating disorders or to treatment with medicinal products that may cause weight gain
- Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
- Inflammatory bowel disease
- Congestive heart failure, New York Heart Association (NYHA) class III-IV
- Diabetic gastroparesis
- History of or current diagnosis of pancreatitis (acute and/or chronic) or pancreatic cancer
- History of cancer with the exception of in-situ malignancies of the skin or cervix uteri
- History of major depressive disorder, a PHQ-9 (Patient Health Questionnaire-9) score of more than 15, or a history of other severe psychiatric disorders or diagnosis of an eating disorder
- Subjects with a lifetime history of a suicide attempt or history of any suicidal behaviour within the past month before entry into the trial
- Inability to speak Danish fluently
- A mental state impeding compliance with the program
- Use of opioids or similar strong analgesics
- Allergic reactions to the active ingredients of Saxenda, such as hypotension, palpitations, dyspnoea and oedema
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Liraglutide 3 mg
Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.
|
Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks
|
Placebo Comparator: Liraglutide 3 mg placebo
Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
|
Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in advanced glycation end products in the skin
Time Frame: week 0 to 52
|
advanced glycation end products levels will be measured on the skin of the volar side of the forearm using skin auto fluorescence
|
week 0 to 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in advanced glycation end products in the skin
Time Frame: week -8 to 0 (pre-randomisation weight loss intervention)
|
advanced glycation end products levels will be measured on the skin of the volar side of the forearm using skin auto fluorescence.
|
week -8 to 0 (pre-randomisation weight loss intervention)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Henrik R Gudbergsen, MD, PhD, The Parker Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 137.02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis, Knee
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
Tianjin XinChen-Techfields Pharma Co., LTD.Completed
-
Eun Jung KimMinistry of Health & Welfare, Korea; Semyung UniversityUnknownOsteoarthritis KneeKorea, Republic of
-
Thammasat UniversityCompletedPrimary Knee OsteoarthritisThailand
-
Galderma R&DCompletedUnilateral Knee OsteoarthritisUnited Kingdom
Clinical Trials on Liraglutide 3 mg (Saxenda)
-
Woman'sNovo Nordisk A/SCompletedPolycystic Ovary Syndrome | Pre Diabetes | Obesity AndroidUnited States
-
Henrik GudbergsenCompletedObesity | OsteoarthritisDenmark
-
Henrik GudbergsenNovo Nordisk A/S; Cambridge Weight Plan LimitedCompleted
-
Henrik GudbergsenCompletedUltrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance (US-LOSEIT-II)Obesity | OsteoarthritisDenmark
-
Henrik GudbergsenCompletedObesity | OsteoarthritisDenmark
-
Anders Fink-Jensen, MD, DMSciCompletedFeasibility | Overweight and Obesity | Metabolic Disturbance | Mental Disorder | LiraglutideDenmark
-
Federico II UniversityUnknown
-
Mayo ClinicNovo Nordisk A/SActive, not recruiting
-
University College, LondonCompleted
-
Beth Israel Deaconess Medical CenterActive, not recruiting